Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

7-oh-cannabidiol (7-oh-cbd) and/or 7-oh-cannabidivarin (7-oh-cbdv) for use in the treatment of epilepsy

a technology of cannabis and cannabinoids, which is applied in the field of 7ohcannabinoids (7ohcbd) and/or 7ohcannabinoids (7ohcbdv) for use in the treatment of epilepsy, can solve the problems of difficult treatment, cognitive, behavioral and motor delays, and inability to obtain seizure freedom

Inactive Publication Date: 2017-07-27
GW RES LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes the use of two compounds, 7-hydroxy-cannabidivarin (7-OH-CBDV) and 7-hydroxy-cannabidol (7-OH-CBD), in the treatment of epilepsy. These compounds have been isolated and / or synthesized in pure form and are proposed for use as medications. The patent also describes pharmaceutical compositions containing these compounds for oral or other modes of administration. The technical effects of this patent include the potential for improved treatment of epilepsy with these compounds, either alone or in combination with other anti-epileptic drugs. The dosage and administration route will depend on the age and needs of the patient.

Problems solved by technology

However, 30% of this patient group, (Eadie et al., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from “treatment-resistant epilepsy” (TRE).
Individuals who develop epilepsy during the first few years of life are often difficult to treat and as such are often termed treatment-resistant.
Children who undergo frequent seizures in childhood are often left with neurological damage which can cause cognitive, behavioral and motor delays.
Childhood epilepsy can be caused by many different syndromes and genetic mutations and as such diagnosis for these children may take some time.
However no data is presented to support the use of 7-OH-CBD as an anti-convulsant.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 7-oh-cannabidiol (7-oh-cbd) and/or 7-oh-cannabidivarin (7-oh-cbdv) for use in the treatment of epilepsy
  • 7-oh-cannabidiol (7-oh-cbd) and/or 7-oh-cannabidivarin (7-oh-cbdv) for use in the treatment of epilepsy
  • 7-oh-cannabidiol (7-oh-cbd) and/or 7-oh-cannabidivarin (7-oh-cbdv) for use in the treatment of epilepsy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Efficacy of 7-Hydroxy Cannabidiol (7-OH-CBD) and 7-Hydroxy Cannabidivarin (7-OH-CBDV) in the Ptz Model of Seizure

Materials and Methods

Compounds:

[0054]The compounds 7-OH CBD and 7-OH-CBDV have never been tested in a model of epilepsy and as such the effects were examined at one dose level in order to determine efficacy.

[0055]The hydroxy-metabolites of CBD and CBDV were also tested against their parent cannabinoids which were used as positive controls. The table below details the doses used in this study.

CompoundDose (mg / kg)Vehicle—CBDV2007-OH-CBDV200CBD1007-OH CBD100

General Methodology for PTZ Model

Animals

[0056]Male Wistar rats (P24-29; 75-110 g) were used to assess the effects of the cannabinoids listed above on the PTZ model of generalised seizures. Animals were habituated to the test environment, cages, injection protocol and handling prior to experimentation. Animals were housed in a room at 21° C. on a 12 hour light: dark cycle (lights on 0900) in 50% humidity, with free access ...

example 2

Efficacy of 7-Hydroxy Cannabidivarin (7-OH-CBDV) in the Maximal Electroshock (Mes) Model of Seizure

Preparation of Test and Reference Compounds

[0072]The vehicle used in this study was 2:1:17 (ethanol:Cremophor:0.9% w / v NaCl). The test compound used was 7-OH-CBDV. This was made to a solution at the highest concentration; then dissolved in ethanol before combination with Cremophor and 0.9% NaCl in the proportion described above. The 7-OH-CBDV was administered intraperitoneally at a volume of 10 ml / kg body weight.

Test System

[0073]Animal Species / Strain: Mouse / ICR, Microbiological grade: SPF, Inc. Sex: male, Age (at time of testing): 5-7 weeks old, Number of animals: about 5 animals per group. Temperature: 23±2° C., Humidity: 60±10%, Light conditions: 7 AM to 7 PM for the light period, 7 PM to 7 AM for the dark period. Chow and water: Free access to CRF-1 (Oriental Yeast Co, Ltd) and tap water.

Experimental Procedures

[0074]One day before each experiment, mice were weighed and randomized in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
w/waaaaaaaaaa
w/waaaaaaaaaa
humidityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and / or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.

Description

[0001]The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and / or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy.[0002]Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.BACKGROUND TO THE INVENTION[0003]Epilepsy occurs in approximately 1% of the population worldwide, (Thurman et al., 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et al., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from “treatment-resistant epilepsy” (TRE).[0004]There are several different types of AED available to treat epilepsy, some of the most common AED defined by their mechanisms of action are described in the following tables:Examples of Narrow Spectrum AED[0005]Narrow-spectrum AEDMechanismPhenytoinSodiu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/05A61K9/08A61K9/00A61K45/06
CPCA61K31/05A61K9/0019A61K9/08A61K45/06A61P25/08A61K36/185A61K47/10A61K47/44A61K2300/00
Inventor STOTT, COLINJONES, NICKWHALLEY, BENJAMINSTEPHENS, GARYWILLIAMS, CLAIRE
Owner GW RES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com